Drug intelligence / Profile preview

RZ-003

Development stage: Preclinical
Lead developer: Rznomics
Modality: Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RZ-003 is a gene therapy drug candidate developed by Rznomics. It utilizes ribozyme-based RNA editing technology as part of a platform for gene transference therapies. The primary indication under development for RZ-003 is Alzheimer’s disease. The drug is in the preclinical stage and leverages advanced RNA editing mechanisms to potentially correct or modulate disease-related genetic sequences[1][2][4].

Beyond the preview

Go deeper on RZ-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RZ-003.

Explore the full profile